Upstream Bio Sets Phase 3 Plans for Verekitug in Asthma
WALTHAM, Mass., Sept. 1, 2026 Upstream Bio, Inc. has announced its pivotal Phase 3 development plans for verekitug in...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WALTHAM, Mass., Sept. 1, 2026 Upstream Bio, Inc. has announced its pivotal Phase 3 development plans for verekitug in...
BROOKLYN PARK, Minn., June 11, 2026 Airiver Medical has announced the successful treatment of the first patient in its...
LONDON, UK, April 8, 2026 GSK has announced that China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab),...
THOUSAND OAKS, Calif., October 17, 2025 — In a landmark regulatory decision, the U.S. Food and Drug Administration (FDA)...
